Allogene Therapeutics ALLO License — Revenue, remaining performance obligation, amount

Similar metrics at other companies

ATEXLicense — Remaining performance obligation, amount

$800K—

SUPNLicense — Revenue, remaining performance obligation, variable consideration amount

$470M—

PEGASubscription license — Revenue remaining performance obligation

$78.44M+73.6%

MLTXLicense — Revenue remaining performance obligation additional variable consideration amount

$344.3M+6.2%

ICUISoftware revenue — Revenue, Remaining Performance Obligation, Amount

$6.28M-27.4%

WBDContent Licensing Contracts — Remaining performance obligations

$4.53B—

Questions, answered.

What is Allogene Therapeutics's license — revenue, remaining performance obligation, amount?

Allogene Therapeutics (ALLO) reported license — revenue, remaining performance obligation, amount of $4.6M in Q1 2026.

How has Allogene Therapeutics's license — revenue, remaining performance obligation, amount changed year-over-year?

Allogene Therapeutics's license — revenue, remaining performance obligation, amount decreased by 0.0% year-over-year, from $4.6M to $4.6M.

What does license — revenue, remaining performance obligation, amount mean?

This metric quantifies the total transaction price allocated to performance obligations that are partially or fully unsatisfied at the end of the reporting period for licensing arrangements. It reflects the aggregate value of future services or rights that the company is obligated to provide to partners under existing contracts. Tracking this balance helps investors assess the visibility and stability of future revenue streams derived from the company's intellectual property and collaborative partnerships.